Contribution of vitamin A to the oxidation resistance of human low density lipoproteinsM. A. Livrea, Antonio Riccio, Luisa Tesoriere et al.|Free Radical Biology and Medicine|1995Cited by 61
Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).María‐Victoria Mateos, Vânia Hungria, Vera Zherebtsova et al.|Journal of Clinical Oncology|2024Cited by 21